6IO Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Sustained International GrowthConsistent double-digit international growth indicates expanding geographic reach and durable demand beyond the U.S. market. This diversification can reduce reliance on domestic channels, support future unit volume, and provide a broader base for scaling Inogen’s respiratory-care portfolio.
New Product Adoption And Margin ImprovementEarly adoption of Voxi and Aurora provides evidence that product innovation is contributing to commercial growth rather than relying solely on legacy devices. Combined with higher gross margin, successful launches could improve mix, strengthen competitiveness, and support more sustainable profitability.
Strong Liquidity And No DebtA substantial cash position and absence of debt give Inogen meaningful financial flexibility while it invests in products, geographic expansion, and execution improvements. Recent positive quarterly cash generation also provides some support for funding operations without near-term leverage pressure.
Bears Say
Loss-making Operations And Inconsistent Cash GenerationThe revenue recovery has not yet translated into durable GAAP earnings or consistently self-funded operations. Continued losses and recurring free-cash-flow deficits could consume liquidity over time, constrain investment capacity, and leave the turnaround dependent on further execution improvements.
Structural U.S. Channel And Rental PressureThe shift away from direct-to-consumer sales and traditional rentals affects important commercial channels, not merely one quarter’s demand. If B2B growth only partially offsets these declines, channel mix may continue to restrain revenue growth and challenge the company’s path to scale.
Lower Revenue Outlook And Execution UncertaintyThe guidance reduction signals that current growth initiatives are not fully offsetting channel and purchasing headwinds. Dependence on distributor order timing can make reported revenue less predictable, complicating planning and increasing the risk that operating leverage develops more slowly than expected.
Inogen News
6IO FAQ
What was Inogen’s price range in the past 12 months?
Currently, no data Available
What is Inogen’s market cap?
Inogen’s market cap is CHF118.39M.
When is Inogen’s upcoming earnings report date?
Inogen’s upcoming earnings report date is Nov 11, 2026 which is in 43 days.
How were Inogen’s earnings last quarter?
Inogen released its earnings results on Aug 06, 2026. The company reported -CHF0.113 earnings per share for the quarter, beating the consensus estimate of -CHF0.124 by CHF0.011.
Is Inogen overvalued?
According to Wall Street analysts Inogen’s price is currently Undervalued.
Does Inogen pay dividends?
Inogen does not currently pay dividends.
What is Inogen’s EPS estimate?
Inogen’s EPS estimate is -0.11.
How many shares outstanding does Inogen have?
Inogen has 26,538,338 shares outstanding.
What happened to Inogen’s price movement after its last earnings report?
Inogen reported an EPS of -CHF0.113 in its last earnings report, beating expectations of -CHF0.124. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Inogen?
Currently, no hedge funds are holding shares in CH:6IO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inogen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF10.78 (― Upside)
CHF10.78 (― Upside)
Blogger Sentiment
Bullish
CH:6IO Sentiment 100%
Sector Average 64%
Sector Average 64%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.81%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.48%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inogen
Inogen, Inc. operates as a medical technology enterprise dedicated to designing, fabricating, and distributing oxygen concentration equipment. These cutting-edge devices are engineered to provide continuous oxygen support for patients managing persistent respiratory conditions. The company's diverse product range features the popular portable Inogen One, which efficiently draws oxygen from the surrounding atmosphere to offer an independent supply, alongside stationary Inogen At Home concentrators, Tidal Assist Ventilators, and various associated accessories. Inogen serves a broad clientele, including individual patients, medical professionals, and insurance providers, both domestically in the United States and globally. Furthermore, the company facilitates direct equipment rentals to patients. Founded in 2001, Inogen, Inc. is headquartered in Goleta, California.
6IO Company Deck
6IO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted clear commercial and product progress — notably strong international revenue growth (+15% YoY), continued POC unit expansion (>12% YoY), early traction for new products (Voxi shipments >5,000; Aurora account count doubled), margin improvement (adjusted gross margin +65 bps) and a raised adjusted EBITDA outlook. Offsetting these positives are ongoing headwinds in the U.S. DTC channel (U.S. sales -2% YoY), a 12% decline in rental revenue, a downward revision to full-year revenue guidance (midpoint reduction of ~ $11.5M), and continued dependency on distributor purchase timing and reimbursement/regulatory milestones. Overall the company shows momentum in strategic growth areas and improved unit economics, but macro and channel mix pressures keep near-term top-line growth constrained.View all CH:6IO earnings summaries